Afficher la notice abrégée

Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence

dc.rights.licenseopenen_US
dc.contributor.authorROUSTIT, M.
dc.contributor.authorGUILHAUMOU, R.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOLIMARD, Mathieu
dc.contributor.authorDRICI, M. D.
dc.contributor.authorLAPORTE, S.
dc.contributor.authorMONTASTRUC, J. L.
dc.date.accessioned2021-02-15T14:30:07Z
dc.date.available2021-02-15T14:30:07Z
dc.date.issued2020
dc.identifier.issn1958-5578 (Electronic) 0040-5957 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26249
dc.description.abstractEnChloroquine and hydroxychloroquine are drugs that have shown in vitro activity on the replication of certain coronaviruses. In the context of the SARS-Cov-2 epidemic, the virus responsible for the novel coronavirus disease (COVID-19), these two drugs have been proposed as possible treatments. The results of the first clinical studies evaluating the effect of hydroxychloroquine do not support any efficacy of this drug in patients with COVID-19, due to major methodological weaknesses. Yet, these preliminary studies have aroused considerable media interest, raising fears of massive and uncontrolled use. In the absence of evidence of clinical benefits, the main risk is of exposing patients unnecessarily to the well-known adverse effects of hydroxychloroquine, with a possibly increased risk in the specific setting of COVID-19. In addition, widespread use outside of any recommendation risks compromising the completion of good quality clinical trials. The chloroquine hype, fueled by low-quality studies and media announcements, has yielded to the implementation of more than 150 studies worldwide. This represents a waste of resources and a loss of opportunity for other drugs to be properly evaluated. In the context of emergency, rigorous trials are more than ever needed in order to have, as soon as possible, reliable data on drugs that are possibly effective against the disease. Meanwhile, serious adverse drug reactions have been reported in patients with COVID-19 receiving hydroxychloroquine, justifying to limit its prescription, and to perform suitable cardiac and therapeutic drug monitoring.
dc.language.isoENen_US
dc.subjectPharmacoEpi-Drugs
dc.title.enChloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence
dc.title.alternativeTherapieen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.therap.2020.05.010en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32473812en_US
bordeaux.journalThérapieen_US
bordeaux.page363-370en_US
bordeaux.volume75en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03141834
hal.version1
hal.date.transferred2021-02-15T14:30:12Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Th%C3%A9rapie&rft.date=2020&rft.volume=75&rft.issue=4&rft.spage=363-370&rft.epage=363-370&rft.eissn=1958-5578%20(Electronic)%200040-5957%20(Linking)&rft.issn=1958-5578%20(Electronic)%200040-5957%20(Linking)&rft.au=ROUSTIT,%20M.&GUILHAUMOU,%20R.&MOLIMARD,%20Mathieu&DRICI,%20M.%20D.&LAPORTE,%20S.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée